Loading clinical trials...
Loading clinical trials...
To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
Primary Objective: • To determine the feasibility and turnaround of clinical WES and transcriptome sequencing Secondary Objectives: * To determine the frequency of actionable DNA and RNA alterations * To determine the concordance of DNA and RNA alterations * To determine the frequency of molecularly matched therapy * To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling * To determine the feasibility of molecularly matched therapy to acquired resistance alterations Exploratory Objectives: * To determine the feasibility of prioritizing targets with precision analytics * To determine clinical outcomes in patients receiving molecularly matched therapy * To determine the role of additional emerging diagnostic technologies
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
July 7, 2022
Primary Completion Date
May 12, 2027
Completion Date
May 12, 2027
Last Updated
March 4, 2026
111
ACTUAL participants
Molecular Functional Portrait
OTHER
Lead Sponsor
M.D. Anderson Cancer Center
NCT06337318
NCT07388563
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions